RxDoctor Payments Data

Robert Huang, MD

Interventional Cardiology · Chattanooga, TNNPI 1477596328

Payments from drug & device makers

$14,255in general payments, 2019–2025

Across 251 payments — averaging $56.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$7K
  • Abiomed$2K
  • Novartis$1K
  • Boston Scientific$875
  • Medtronic$431
  • Abbott$430
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$6,60046%
  • Travel & lodging$6495%
  • Food & beverage$6,95249%
  • Education$540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,255 in reported general payments places this provider in the 60th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$159,922
Medicare patients
1,367
Services billed
2,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban561$579,723
EntrestoSacubitril/Valsartan262$315,407
XareltoRivaroxaban128$140,933
Repatha SureclickEvolocumab35$47,584
JardianceEmpagliflozin37$40,333
FarxigaDapagliflozin Propanediol15$16,470
BrilintaTicagrelor23$15,129
Ranolazine ErRanolazine67$10,099
Atorvastatin Calcium765$8,704
Metoprolol Succinate517$8,260
Prasugrel Hcl42$6,069
Carvedilol771$5,316
Rosuvastatin Calcium372$5,098
Potassium Chloride200$4,299
NexlizetBempedoic Acid/Ezetimibe11$4,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$579,723561 claims
NovartisEntresto$1,245$315,407262 claims
Johnson & JohnsonXarelto$165$140,933128 claims
Boehringer IngelheimJardiance$23$40,33337 claims
AstraZenecaFarxiga, Brilinta$327$31,59938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →